Downstream processing (DSP) describes the series of operations required to take biological materials such as cells, tissue culture fluid, or plant tissues, and derive from them a pure and homogeneous protein product.
Rise in demand for biopharmaceuticals and increase in R&D expenditure for biopharmaceutical companies drive the growth of the global downstream processing market. On the other hand, dearth and shortage of skilled bioprocess engineers restrain the growth to some extent. However, emerging markets such as China and India offer lucrative opportunities in the industry.
The global Downstream Processing Market was estimated at $21.8 billion in 2020 and is expected to hit $92.0 billion by 2030, registering a CAGR of 13.5% from 2021 to 2030.
Covid-19 scenario-
- Rise in demand for Covid-19 vaccines across the world impacted the global downstream processing market positively, since downstream process is an important method utilized for the production of vaccines.
- The key players in the industry also heightened their production to cater to the demand for products.
The key market players analyzed in the global downstream processing market report include Danaher Corporation, Repligen Corporation, Thermo Fisher Scientific Inc., Merck & Co., Inc., Boehringer Ingelheim, Lonza Group AG, Eppendorf AG, 3M Company, Finesse Solutions, Inc., and Sartorius Stedim Biotech S.A. These market players have incorporated several strategies including partnership, expansion, collaboration, joint ventures, and others to brace their stand in the industry.
